Turkey Slashes Prices Yet Again, Pharmas Prepare For Worst Case Scenario
This article was originally published in PharmAsia News
A third round of price cuts and substantial currency depreciation has manufacturers questioning investment in Turkey.
You may also be interested in...
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
The Turkish Social Security Institution or SGK hiked institutional pharmaceutical discounts with a new regulation in December 2010, imposing an additional 9.5% price cut to its reference pricing system
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.